SpotMix™ Antigen Discovery Pools consist of overlapping & pooled peptides synthesized by our proprietary ultra-high throughput SPOT technology. SPOT peptides are synthesized in small amounts fully automated and are purified by dialysis. Therefore, we are able to provide SpotMix™ and SpotMix™ PLUS Pools very quickly and at low cost. SpotMix™ Pools are optimal for broad antigen target discovery, T-cell epitope discovery and biological screening. SpotMix™ PLUS Pools have also been used for neo-epitope based immune monitoring.
Have a look at all our Epitope Discovery & Target Discovery Tools for Development of Cell- and Immunotherapy
||Varying (approx. 5 to 20 µg / peptide depending on synthesis yield)||10 µg / peptide (each peptide quantified)||From 1 mg / peptide (each peptide quantified)|
||Purified by Dialysis||Purified by Dialysis||Unpurified or purified by HPLC up to GxP grade|
||5% peptides analyzed by LC-MS||100% peptides analyzed by LC-MS||100% peptides analyzed by LC-MS|
||none||none||Full QC for each peptide pool warranting presence of each peptide|
||Antigen discovery||Neo-epitope based immune monitoring, Antigen discovery||Clinical immune monitoring, preclinical & clinical research, immunotherapy|
||From 2 weeks||From 3 weeks||From 4 weeks|
- Antigen target discovery
- Biological screening
- Neo-epitope based immune monitoring
A Fast & Low Cost Process for Neo-Epitope Based Immune Monitoring
by Evelyna Derhovanessian, BioNTech AG, Mainz, Germany
- Quick production
- Parallel production of thousands of peptides resulting in hundreds of peptide pools
- Most inexpensive custom peptide pools in the market
Read more References with SpotMix™
PepSup™ : A NEW Peptide Based Cell Activation Kit
PepSup™ will bring your cellular assays to the next level of standardization and reproducibility!
Become a Peptide Design Expert!
Read our new peptide library and peptide pool design guidelines and make use of our free software tools.
Two new breakthrough papers in NATURE feature JPT's peptides in immunotherapeutic workflows!
Read more: (July 2017)